STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Good morning and welcome to Bausch + Lomb’s Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event ...

including Biotrue and SofLens. We are still impressed at the overall performance and believe the firm's share in the contact lens market slightly increased. Miebo and Xiidra, Bausch & Lomb's dry ...

Bausch & Lomb is one of the largest vision care companies ... We expect patents and product superiority of Biotrue eye drops, Lumify, and PreserVision to secure Bausch as a leader in the over ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Private equity groups TPG and Blackstone have teamed up to work on a joint bid for eyecare company Bausch ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...